Teva denies big layoffs are planned, but will push greater efficiency and shutter floundering efforts
With its executive suite in turmoil, its flagship drug under attack and its books burdened by debt following years of drought in its R&D arm, Teva is reportedly preparing to unleash a major reorganization that will cost thousands of jobs. But after first staying mum on the subject, the Israeli pharma company now says it isn’t bringing out the ax but will instead pursue a variety of efficiency measures.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.